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Background/Abstract. Immune responses initiated by T cell receptor (TCR) and costimulatory molecule mediated signaling
culminate in maximal cytokine mRNA production and stability. The transcriptional responses to co-stimulatory T cell signalling
involve calcineurin and NF-AT, which can be antagonized by interference with the cis-trans peptidyl-prolyl isomerases (PPIase),
cyclophilin A and FKBP. Signalling molecules downstream of CD28 which are essential for the stabilization of cytokine mRNAs
are largely unknown. Methodology/Principal Findings. We now show that Pin1, a third member of the PPIase family
mediates the post-transcriptional regulation of Th1 cytokines by activated T cells. Blockade of Pin1 by pharmacologic or
genetic means greatly attenuated IFN-c, IL-2 and CXCL-10 mRNA stability, accumulation and protein expression after cell
activation. In vivo, Pin1 blockade prevented both the acute and chronic rejection of MHC mismatched, orthotopic rat lung
transplants by reducing the expression of IFN-c and CXCL-10. Combined transcriptional and post-transcriptional blockade with
cyclosporine A and the Pin1 inhibitor, juglone, was synergistic. Conclusions/Significance. These data suggest Pin1 inhibitors
should be explored for use as immunosuppressants and employed with available calcineurin inhibitors to reduce toxicity and
enhance effectiveness.
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INTRODUCTION
During and after antigen presentation, inflammatory cytokines
structure the type and amplitude of the T cell response. Especially
important are the type 1 pro-inflammatory cytokines, IFN-c, IL-2
and CXCL-10, which are produced in large amounts after
infection [1] and during allograft rejection [2]. IL-2 promotes the
proliferation and differentiation of T cells whereas IFN-c activates
immune cells and the antigen presentation pathway [3]. CXCL-10
(IFN-c-inducible protein-10) is a potent chemoattractant for
inflammatory cells and modulates adhesion molecule expression.
The production of IFN-c and IL-2 by T cells involves both
transcriptional and post-transcriptional regulation with attenua-
tion of either capable of significantly muting cytokine production
[4,5]. The immunosuppressives cyclosporine A (CsA) and FK506
which bind to Cyclophilin A (CyA) and FKBP12, respectively,
prevent NF-AT mediated cytokine gene transcription [6]. CyA
and FKBP12 are members of the peptidyl-prolyl isomerase
(PPIase) family that catalyze the cis-trans isomerization of X-Pro
peptide bonds. A third PPIase, Pin1, binds to and isomerizes only
phosphorylated Ser/Thr-Pro motifs. Isomerization-induced con-
formational changes alter target protein function, phosphorylation
and turnover [7,8]. The initially identified Pin1 targets were cell
cycle regulators particularly mitotic kinases [9]. Consistent with
such a function, overexpression of Pin1 has been observed in many
cancers, and its levels are predictive of cancer recurrence [10,11].
Recently, we implicated Pin1 in the post-transcriptional control of
GM-CSF mRNA by activated eosinophils and T lymphocytes
[12,13]. GM-CSF is a prototypical proinflammatory cytokine,
whose mRNA is regulated by 39-untranslated AU-rich elements
(AREs). These are also found in and important for the post-
transcriptional control of IL-2 and IFN-c mRNAs [14,15]
suggesting a role for Pin1 in the type 1 immune response. In the
present report, we show that Pin1 KO mice show an alternated
cytokine response, after co-stimulation with anti-CD3 and anti-
CD28. This reflects an inability of T cells to fully stabilize ARE
mRNAs after cell activation. We explore the biology significance
of these observations by testing if Pin1 blockade would alter type 1
immune responses to mismatched organ transplants. We show that
mismatched lung transplants are not rejected if Pin1 is inhibited.
Further, we show that Pin1 blockade is synergistic with calcineurin
inhibitors such as Cyclosporin A. These data establish a new role
for Pin1 in the T cell immune response and point to a novel target
for immunosuppression.
RESULTS
Pin1 function on type 1 cytokine and chemokine expression was
first evaluated in Pin1 knockout (KO) mice. Splenocytes from KO
mice activated with anti-CD3 plus anti-CD28, which normally
triggers cytokine mRNA stabilization and accumulation [4,13],
showed significantly less IFN-c and IL-2 mRNA compared to WT
(p,0.03 and p,0.008, respectively) while CXCL-10 mRNA was
reduced by 50% but did not quite reach significance (figure 1A).
Secreted IFN-c was proportionally reduced (4-fold) in the
supernatant of KO splenocyte cultures compared to WT
(figure 1B). Bulk analysis of activated KO CD4+ or CD8+
splenocytes by flow cytometry showed reductions in IL-2 and IFN-
c positive cells (figure 1C) compared to splenocytes from
heterozygote mice. In KO mice, no differences were noted in
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cell populations or activation marker expression after stimulation
(not shown), eliminating developmental differences between WT
and KO mice. As CD3 mediated signaling is necessary for T cell
development, these data suggest TCR function is likely normal in
Pin1 KO animals. Instead, these data suggested Pin1 was involved
in co-stimulatory-CD3/CD28 signaling. Indeed, IFN-c and IL-2
mRNAs were less stable in anti-CD3/anti-CD28 activated KO
than WT splenocytes while the stability of CXCL-10 mRNA,
which lacks AREs was unchanged (figure 1D and not shown).
Therefore, Pin1 is necessary for ARE mediated cytokine mRNA
stabilization after T cell co-stimulation. As Pin1 substrates also
include NF-kB and NF-AT [16], which regulate cytokine mRNA
transcription, the observed reductions in CXCL-10 suggest
a nuclear event.
Pin1 can be selectively blocked by juglone (5-hydroxy-1,4-
naphthoquinone), which covalently binds to and irreversibly
inhibits Pin-1 activity but has no effect on CyA or FKBP [17].
Prior to its use in vivo, WT and KO thymocytes were activated with
anti-CD3/anti-CD28 while rat splenocytes were treated with
ionophore/PMA (I/P) (figures 1E, 2 and not shown). After
4 hours of I/P, cytokine mRNAs increased by as much as 500 fold
(IFN-c. IFN-c and IL-2 mRNA levels were reduced in the rat or
mouse WT cells by 70–95% after treatment with juglone
(figures 1E, 2A, and 2B). However, juglone had no significant
effect on the abundance of IL-2, IFN-c or the housekeeping RNAs
in Pin1 KO cells (figure 1E and not shown), demonstrating the
specificity of this drug. At the concentrations used here neither
CyA nor FKBP12 peptidyl-prolyl isomerase activities are affected
[17]. Juglone (1 mM) completely blocked the accumulation of I/P-
induced IFN-c and IL-2 mRNAs by rat splenocytes without
altering actin (figure 2A). At lower juglone concentrations
(0.1 mM), only the accumulation of IFN-c mRNA was significantly
inhibited (figure 2A). These data suggest a variable sensitivity of
cytokine mRNAs to Pin1 inhibition. The accumulation of IL-2
and IFN-c after juglone were dramatically reduced in the culture
supernatants (figure 2B). The failure to produce cytokines was
not a function of cell death as equivalent levels of viability were
observed in I/P versus I/P/juglone treated splenocytes
(figure 2C).
In order to characterize Pin1 function during an in vivo type I
immune response, we used the widely employed F344 to WKY
rat, MHC Class I mismatched, orthotopic, single lung trans-
plantation model [18,19]. The donor organ is attached via cuffs to
the recipient’s bronchial and vascular systems permitting normal
function. Nonimmunosuppressed recipients experience profound
acute rejection within several days largely mediated by IFN-c and
CXCL-10 upregulation [20–24]. Over several weeks, chronic
rejection occurs with alveolar, pleural, and peribronchial collagen
deposition, loss of viable pneumocytes and eventual organ loss.
Recipients were given a daily, single intraperitoneal (IP) injection
of 1 mg/kg juglone dissolved in ethanol and diluted in 5 ml saline,
while controls received diluents only. This doses of juglone had no
effect on red cell mass, white cell counts, serum chemistries, liver
function tests, or renal function in control, untransplanted rats
(not shown). Therefore juglone administration appeared to be
safe and nontoxic. Treatment was started the day of the transplant.
At day 7 or 14, animals were sacrificed and the lungs evaluated
grossly and by histopathology. In untreated animals, the transplant
was visibly shrunken and the pleural surfaces hemorrhagic
(figure 3). Palpation revealed a firm and unyielding consistency.
The juglone treated animals showed no gross signs of rejection
(figure 3) and was indistinguishable from the contralateral
control. Microscopically, the untreated transplanted lung showed
Figure 1. Cytokine expression is downregulated in Pin12/2 mouse. A/
Splenocytes from Pin12/2mice (KO) or wild-type mice (WT) were
activated for 3 hours with anti-CD3 plus anti-CD28. mRNAs for IFN-c, IL-
2 or CXCL10 were analyzed by reverse transcription, qPCR. Fold change
increase in activated compared to resting cells were assessed and
averages6SD from 3 mice in each groups are presented. B/ Splenocytes
were activated as in (A) for 5 hours and IFN-c amounts in the cultures
were measured by ELISA. Averages6SD from 3 mice in each groups are
presented. C/ Percentage of IFN-c and IL-2 positive CD4+ and CD8+ cells
in splenocytes activated for 5 hours with anti-CD3. Splenocytes were
incubated for 30 min at 4uC with relevant antibodies at saturation and
then washed and analyzed using a FACSCalibur instrument (Becton
Dickinson, Mountain View, CA). KO mice (2/2) are compared to
heterozygote mice (+/2) and a representative experiment is shown D/
Splenocytes from the same mice (n=3) were activated with anti-CD3
plus anti-CD28 for 3 hours before treated with actinomycin D (Act
D;10 mg/ml). mRNA levels were determined by qPCR at the indicated
times after Act D. IFN-c mRNA levels at T0 were normalized to 100%. E/
Thymocytes from Pin12/2 (KO) or wild-type (WT) mice were activated
with anti-CD3 plus anti-CD28 for 3 hours with or without juglone
(1 mM). mRNA levels were determined by qPCR and presented as
relative (%) expression of IFN-c in juglone-treated cells compared to
activated. * denotes p,0.05.
doi:10.1371/journal.pone.0000226.g001
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dominantly composed of neutrophils, lymphocytes and macro-
phages. Alveolar architecture was totally effaced and the small
airways packed with inflammatory cells (figure 3). These changes
were completely absent in juglone treated animals, which showed
normal alveolar architecture, pleural thickness, and airway
patency (figure 3). Occasional round macrophages were present
in some alveoli. No significant difference was found in the relative
proportion of CD4, CD8 or cd T cells in blood and BAL fluid
from the native right lung or the transplanted left lung, 7 days after
transplantation in juglone treated or untreated animals (not
shown and figure 4A). This is in contrast to collagen V tolerized
animals that show predominantly CD4
+ T cells [25]. These data
demonstrate that Pin1 blockade can dramatically attenuate acute
transplant rejection.
One week after transplantation the levels of IFN-c, and IL-2 in
the bronchoalveolar fluid (BAL) were reduced (figure 4B). These
data suggest that Pin1 blockade prevented cytokine production by
T cells, which were the majority population within the BAL fluid
(not shown). Since draining lymph nodes are a predominant site
for immunological reactivity we analyzed mediastinal lymph node
cells for the expression of cytokine mRNAs by qPCR. mRNAs
coding for IFN-c, IL-2, and CXCL-10 were significantly lower in
juglone treated animals than controls whereas IL-4 was not
significantly affected (figure 4C). IFN-c ELISPOTS of whole
spleen showed large reductions in the juglone treated animals from
untreated controls (figure 4D). At day 7, Pin1 PPIase activity and
amount were attenuated in BAL cells and draining lymph nodes in
juglone treated rats (figure 5A–C). Once inactivated by juglone,
Pin1 is rapidly degraded by the proteasome [12]. Therefore, Pin1
Figure 2. Cytokine mRNAs are suppressed by Pin1 inhibition in activated rat splenocytes. A/ mRNAs for IFN-c, IL-2, and CXCL-10 were analyzed in
splenocytes by reverse transcription, qPCR. Cells were cultured for 4 hours without activation (resting), or with ionophore plus PMA (I/P) or I/P plus
juglone (I/P/J) at 1 or 0.1 mM. The ionomycin/PMA stimulated sample was normalized to 100 and others expressed as a % of that value. The data are
averages6SEM of 3 independent experiments using splenocytes of untreated healthy animals. B/ Secreted IFN-c and IL-2 after 24 hours from the
cultures as described in (A). The data are averages6SEM of 3 independent experiments using splenocytes of untreated healthy animals. C/ Viability of
rat splenocytes treated as above for 24 hr, incubated with propidium iodine and analyzed by flow cytometry.
doi:10.1371/journal.pone.0000226.g002
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throughout the immune system and acute graft rejection after lung
transplantation. The profound suppression of CXCL-10 pre-
sumably reflects both reductions in IFN-c, which normally induces
CXCL-10 as well as direct effects of Pin1 on CXCL-10 expression.
The expression of these cytokines has been highly correlated
with rejection in both animal models and humans [20,21]. In
order to demonstrate a causal role, IFN-c and CXCL-10 expres-
sion vectors were combined and insufflated into donor lungs
immediately before religature in the recipient. To avoid potential
Pin1 mediated, post-transcriptional regulation, only the coding
region without the 39 UTR was inserted downstream of
a constitutively active CMV promoter. By 1 week after transplant,
the lung grafts underwent significant rejection in untreated
controls, which was prevented by juglone (figure 3). The forced
expression of IFN-c and CXCL-10 in juglone treated rats resulted
in severe cellular infiltration irrespective of Pin1 blockade
(figure 5D). Transgenic cytokines were detectable in the BAL
at comparable levels to that seen in untreated recipients (not
shown). These results support a central role of IFN-c and
CXCL-10 in the process of acute rejection and suggest that
Figure 3. Pin1 is required for acute and chronic rejection. I and IV: Gross
appearance of lungs from control, untreated transplants (I) and juglone
treated (1 mg/kg) (IV). Lungs are oriented so that transplant is on the
left. II and V: Hematoxylin and eosin stained sections from control
untreated (II) or juglone treated (V) 1 week after transplant. III and VI:
Trichrome stained sections of control, untreated (III) and juglone
treated (VI) two weeks after transplant. These are representative
sections from 8 control and 8 juglone treated transplant recipients in
each set.
doi:10.1371/journal.pone.0000226.g003
Figure 4. IFN-c and IL-2 are Pin1 dependent. A/ Relative percentage of
CD4, CD8 and cd T lymphocytes in BAL cells from the transplanted lung.
BAL cells were prepared from control and juglone-treated rats as
described above and the percentage of CD4+,C D 8 + and cd T
lymphocytes were determined by flow cytometry with specific
antibodies. The graph represents an average +/2 SD of 4 experiments.
B/ IFN-c and IL-2 concentrations in concentrated BAL fluid were
determined by ELISA. * denotes p,0.01. C/ Mediastinal lymph nodes
from control or juglone treated animals were used for reverse
transcription, qPCR for the cytokines shown along the x-axis. The
values in untreated controls were normalized to 100% and data shown
represent % change in juglone treated samples. In (B) and (C), the data
shown are an average6SEM of 4 rats in each group 7 days after
transplantation. * denotes p,0.05 from control samples. D/ Spleno-
cytes were isolated and cultured as described in Material and Methods.
IFN-c positive splenocytes were quantitated by Elispot (n=3). * denotes
p,0.05.
doi:10.1371/journal.pone.0000226.g004
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graft sparing.
Immunosuppressive drugs, particularly CsA greatly improves
graft survival but have renal damage as a common side effect [26].
To avoid toxicity and enhance graft acceptance, immunosuppres-
sants such as corticosteroids, calcineurin inhibitors, antimetabo-
lites, and rapamycin are given in combination [26]. Cyclosporine
A and tacrolimus indirectly inhibit nuclear factor of T cells
(NFAT) preventing the transcriptional upregulation of cytokine
genes by activated T cells [26]. In contrast, Pin1 suppresses
expression through the regulation of cytokine mRNA stability.
Given this distinct mode of action, we asked if combined CsA and
juglone therapy would be additive or synergistic. CsA was injected
intraperitoneally for 3 days at a dose of 1 mg/kg together with
0.1 mg/kg of juglone, which was then continued alone for 4 more
days. Cyclosporine is usually used at 25 mg/kg/day for 3 days
which induces long lived lung transplant acceptance in rats while
moderate to severe rejection was observed at doses of 5 mg/kg/
Figure 5. Expression of exogenous IFN-c and CXCL-10 in juglone-treated rats overcomes Pin1 inhibition and results in rejection. A/ BAL fluid cells from
transplanted and untreated controls (X), or juglone treated (m) were quantitated, lysed and used for Pin1 isomerase assay. Juglone (1 mM) was also
added in vitro to equal amounts of the control (e) and juglone treated (n) samples and isomerase assay repeated. B/ Mediastinal lymph nodes from
2 untreated controls (X,e) or one juglone treated animal (m) were lysed and equal amounts of protein used for Pin1 isomerase assay. C/ Immunoblot
with anti-Pin1 or anti-actin of mediastinal lymph nodes from 2 controls, untreated (2juglone) or 2 juglone treated animals (+juglone). D/ Donor lungs
were insufflated with 100 mg each of CXCL10 and IFN-cexpression vectors immediately prior to religation in recipient. Animals were then untreated (I,
II) or treated with juglone at 1mg/kg for 1 week (III, IV) and histopathologic analysis after H & E staining. Representative sections from multiple
animals shown.
doi:10.1371/journal.pone.0000226.g005
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showed modest graft discoloration (Figure 6) but microscopically
severe cellular infiltration diffusely throughout the parenchyma
with foci in peribronchial and perivascular areas (Figure 6).
Similarly, suboptimal inhibition of Pin1 leads to severe rejection
pathology with substantial cellular infiltration and hemorrhage
(Figure 6). In contrast, combined suboptimal treatment with CsA
and juglone provided excellent graft protection without identifi-
able cellular infiltrates (Figure 6). These data show that combined
inhibition of Pin1 and calcineurin are additive or synergistic and
suggest that CsA dosage could be signifcantly reduced if Pin1
inhibition is added to the therapeutic regiment.
DISCUSSION
We recently reported that Pin1 plays a role in the post-
transcriptional control of GM-CSF mRNA expression by activated
eosinophils and lymphocytes. Mechanistically, Pin1 interacts with
and controls the ARE mRNA-binding activity of AUF1. When
associated with AUF1, ARE mRNAs such as GM-CSF are rapidly
catabolized by the exosome preventing translation. Cell activation
rapidly increased Pin1 activity leading to AUF1 isomerization and
loss of mRNA binding. Under these conditions, GM-CSF mRNA
was stabilized and translated [12,13]. These data suggested that
other cytokine mRNAs, particularly those with AREs in their 39
untranslated region might be similarly regulated. Here we show in
vitro, using either Pin1 KO or juglone-treated splenocytes from
WT rats that Pin1 activity is required to stabilize, accumulate and
translate mRNAs coding for several type-1 cytokines including
IFN-c and IL-2. These effects on IFN-c and IL-2 were observed in
vivo after juglone treatment of rats receiving MHC Class I
mismatched, orthotopic, single lung transplants. CXCL-10 in vitro
and IL-4 in vivo mRNA levels were far less affected by Pin1
blockade, suggesting Pin1 regulates only the most labile AU-rich
mRNAs. These results are in agreement with our previous study
showing IL-4 expression is insensitive to Pin1 inhibition [13], and
reinforces the conclusion that Pin1 affects mRNA levels specifically
through ARE-binding proteins [12,13]. In vivo, the profound
suppression of CXCL-10 observed presumably reflects both
reductions in IFN-c, which normally induces CXCL-10 as well
as direct effects of Pin1 on the production of CXCL-10, which
might include nuclear events [16]. Finally, incomplete Pin1
blockade using low dose juglone [13] failed to decrease IL-2
mRNA levels but significantly reduced protein secretion. There-
fore, in addition to stabilization and transcription, Pin1 may affect
the of ARE mRNAs as well.
Pin1 differs from CyA and FKBP12 in uniquely recognizing
phosphorylated Ser/Thr-Pro motifs via a group IV WW domain
and its PPIase is structurally distinct [28]. Unlike CyA and
FKBP12, Pin1 is sensitive to juglone, which irreversibly binds to
cysteines within the isomerase domain [17]. Enzymatic assays
herein demonstrated that Pin1 activity in cell lysates most
proximal to allostimulation (BAL and mediastinal nodes) was
completely suppressed. In vitro, 5.7 mM juglone eliminated
essentially 100% of Pin1’s and highly related yeast and E. coli
Figure 6. Pin1 and calcineurin inhibition are synergistic. Transplants were performed as for figure 3 and animals harvested 7 days later. (I) Treated with
CsA at 1 mg/kg/d for 3 days. (II) Treated with juglone at 0.1 mg/kg/d for 7 days. (III) Treated with CsA at 1 mg/kg/d for 3 days plus juglone at 0.1 mg/
kg/d for 7 days. For all conditions, gross apearance of the transplant at harvest shown along the left, 56and 206representative sections stained with
H & E shown in the middle and right panels.
doi:10.1371/journal.pone.0000226.g006
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concentrations had no effect on cyclophilin A nor FKBP12 [17].
Assuming complete distribution throughout all body water, the
1 mg/kg dose of juglone used here should generate a maximal
concentration of ,10 mM. Therefore, it is very unlikely that
cyclophilin A nor FKBP12 were affected by juglone treatment and
underlie the graft acceptance seen here. While juglone has been
shown to affect other enzymes including RNA polymerase,
pyruvate decarboxylase and glutathione S-transferase [29], none
of these has been implicated in the selective expression of the
subset of cytokine mRNAs downregulated in these experiments.
Were these enzymes or polymerases inhibited, global rather than
selective downregulation of gene expression would be expected.
Therefore, we conclude that the immunosuppressive effects of
juglone in vivo reflect Pin1 blockade. In addition, the specificity of
juglone on IFN-c and IL-2 expression through Pin1 has been
confirmed using T cells from KO mice. Indeed, juglone did not
affect IFN-c and IL-2 expression in activated T cells from these
animals. Importantly, these doses of juglone were nontoxic.
Neither renal, hematology nor liver function tests showed
abnormalities after treatment for 2 weeks. While it is unlikely
juglone would be employed clinically, these data are encouraging
for the development of additional Pin1 inhibitors.
Irrespective of molecular mechanism, suppression of Pin1
clearly prevented acute and chronic graft rejection. Most
prominently absent were inflammatory cells and compensatory
alveolar, pleural and bronchial fibrosis. Based on our data, we
favor three explanations for graft survival after Pin1 inhibition.
First, the production or expression of critical, proinflammatory
chemokines (CXCL-10) and cytokines (IFN-c and IL-2) containing
39 untranslated region AREs were markedly attenuated. CXCL-
10 levels have been well correlated with the rejection by human
recipients of renal, cardiac and lung allografts [20,21,30]. Cardiac
allografts were not rejected if derived from CXCL-10 deficient
donor mice [22] nor if wild type organs were transplanted into
CXCL-10 receptor knockout recipients [31]. Similarly, IFN-c and
CXCL-10 have been highly associated with rejection in human
cardiac and lung allograft recipients [32–34] and the appearance
of IFN-c positive splenocytes predicted the onset of renal transplant
rejection [35]. Therefore, IFN-c and CXCL-10 appear particularly
important for T cell chemotaxis into and propensity to initiate an
anti-graft response. This was directly tested here by constitutive
overexpression of IFN-c and CXCL-10 within the graft and
demonstration that Pin1 blockade was unable to prevent immune
cell infiltration and rejection. Finally, the lack of chronic rejection
and collagen deposition observed here may reflect a role of Pin1 in
TGF-b1 production or signalling to fibroblasts. TGF-b1i n d u c e d
collagen III mRNA was significantly reduced by escalating doses of
juglone (Shen et al., manuscript submitted). The mechanism
underlying this observation is unknown but presumably involves
Smad signalling. These data suggest Pin1 blockade could be effective
in reducing the fibrosis characteristic of BOS, which is seen despite
immunosuppression with CsA, steroids and other agents.
The identification of Pin1 as a potential target for immunosup-
pression could have considerable importance. Most currently
employed drugs have been available for 15 years or more and
despite combined therapy, continue to have significant side-effects.
Based on the data here and previously [12,13], Pin1’s regulation of
immune responses involves post-transcriptional pathways largely
unaffected by CsA or FK506. Therefore, we tested if CsA plus
juglone showed additive effects. Indeed, combined therapy with
suboptimal doses of CsA and juglone showed dramatic inhibition
of graft rejection, demonstrating that these agents could be used
together with effectiveness and possibly lower toxicity.
The data presented here show that Pin1 influences the type I
immune response by modulating the production of proinflamma-
tory, T cell cytokines including IFN-c and IL-2. Based on prior
work, Pin1 likely functions through direct interactions with and
regulation of key AUUUA specific, mRNA binding proteins such
as AUF1, HnRNP C and HuR [12,13]. Interference with Pin1
through pharmacologic or genetic means reduced IFN-c and IL-2
production and substantially attenuated graft rejection. Our data
predict that drug combinations directed at the production (CsA,
FK506, steroids) and decay of cytokine mRNAs would more
effectively suppress alloimmunity and do so with reduced toxicity.
More generally, the broad range of type 1 immune responses such
as infectious diseases (intra and extracellular pathogens) or
autoimmunity (diabetes, multiple sclerosis and lupus) that involve
or require IFN-c suggest a role for Pin1 in these processes as well.
MATERIALS AND METHODS
Reagents
Juglone (5-hydroxy-1,4-naphthoquinone), ethanol, ionomycin and
phorbol myristate acetate (PMA) were from Sigma (Sigma-Aldrich
Chemical Company, St. Louis, MO), isoflurane was from Phoenix
Pharmaceutical Inc. (St. Joseph, MO). Anti-CD3-coated plates,
control plates and the anti-CD28 antibody were provided by BD
Biosciences, Bedford, MA. Cyclosporine A was purchased from
Gallipot, Inc. (St. Paul, MN) through the hospital pharmacy.
Pin1 2/2 mice
Pin1 null mice were originally generated by Fujimori, and the Pin1
deletion was transferred into an isogenic C57BL/6J background
by Jackson Laboratory. Dr. Anthony Means of Duke University
Medical Center generously provided Pin1
+/2 mice to our
laboratory. Mice were housed 2–4 per microisolator cage on
a 6am–6pm light cycle with ad libitum food (Purina 5015 mouse
diet) and water. The cages contained seeds and a neslet as the only
sources of environmental enrichment. All husbandry and eutha-
nasia procedures were performed in accordance with NIH and an
approved University of Wisconsin Madison animal care protocol
through the Research Animal Resources Center. As homozygous
Pin1 mutant mice are infertile, heterozygote mice were mated to
generate WT, heterozygote and knock-out progeny. Genotypes
were determined by PCR analysis of DNA extracted from tail
biopsies taken at the time of weaning (postnatal day 18). The
forward 59-ATCATCCTGCGCACAGAATG-39 and reverse 59-
TCAATTCCTCCAGAAGGAGC-39 primers for the WT pin1
allele and the forward 59-CTTGGGTGGAGAGGCTATTC-39
and reverse 59-AGGTGAGATGACAGGAGATC-39 primers for
the disrupted allele produced 195 and 280 nt PCR products,
respectively. Thymus and spleen were dissected from adult mice
(12 weeks old). Splenocyte and thymocyte suspensions were
prepared using cell strainers from BD Bioscience (San Jose, CA).
Red blood cells were lysed with ammonium chloride.
Transplantation
All experiments were carried out under an approved animal
protocol with F344 and WKY rats weighing 300–350 g (Harlan,
Indianapolis, IN). The animals were housed with 2–3 animals per
cage that were maintained in environmentally controlled rooms at
22uC and 50–55% humidity, with a 12/12h light/dark cycle. All
rats were fed a standard laboratory diet (NIH-07 Rat and Mouse
Chow) and were provided water ad libitum. The animal resource
services facilities are accredited by the American Association for
the Accreditation of Laboratory Animal Care. Animals were
euthanized with an overdose of inhaled isoflurane. The orthotopic
Pin1 Modulates Immune Response
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using the cuff technique [19]. Briefly: rats were anaesthetized by
inhalation of a mixture of isoflurane and oxygen, intubated and
ventilated with a mixture of isoflurane and oxygen to maintain
anesthesia. The donor rat was placed in a supine position and the
heart and lungs were removed en bloc. The left lung was resected
and the pulmonary vein, bronchus, and pulmonary artery were
passed through teflon cuffs and the proximal ends were everted
over the cuffs. On the recipient rat a left thoracotomy was
performed. The donor pulmonary vein, bronchus, and pulmonary
artery were inserted into the corresponding recipient hilar
structures, and fixed with separate circumferential ligatures of
silk. The chest wall was closed, and the isoflurane was stopped.
Juglone and cyclosporine preparation and injection
Juglone was dissolved in 100% ethanol at 14 mM (2.44 mg/ml).
For injection between 100 and 150 ml of this solution (depending
on the animal weight) was diluted in 5 ml saline and injected i.p.
within 30 minutes. For suboptimal dosing between 10 and 25 mlo f
this solution was injected. Control animals received weight
appropriate volume (100–150 ml; 10–25 ml resp.) of 100% ethanol
in 5 ml saline. Cyclosporine A was dissolved in 100% ethanol at
25 mg/ml. For injection 10 to 25 ml of this solution (depending on
the animal weight) was diluted in 5 ml saline and injected prior to
the transplantation and the two following days.
Preparation of lung, lymph nodes and blood
After sacrifice blood was drawn from the abdominal vein into
a heparinized tube. BAL was performed separately in the left
transplanted lung and the right native lung. Lungs were then
remove en bloc and fixed by bronchial infusion of a 1% para-
formaldehyde solution at 30 cm H2O pressure overnight. Medi-
astinal lymph nodes and spleen were removed and cell suspensions
were prepared using cell strainers from BD Bioscience (San Jose,
CA). Red blood cells were lysed with ammonium chloride.
Pin1 activity assay
Activity was measured as described previously [12,13]. White
blood cells from lymph node, spleen, and bronchoalveolar lavage
fluid were lysed by repeated freeze-thaw cycles in a buffer
containing 50 mM HEPES and 100 mM NaCl, pH 7.0. Total
protein (10 mgi n1 0ml) was mixed with 70 ml of HEPES-NaCl
buffer supplemented with 2 mM dithiothreitol and 0.04 mg/ml
BSA. Then, 5 mlo fa-chymotrypsin (60 mg/ml in 0.001 N HCl)
was added and mixed throughly. Finally, 5 ml of the tetrapeptide
substrate Suc-Ala-Glu-Pro-Phe-pNa (Peptides International,
Louisville, Kentucky) dissolved in dimethylsulfoxide and preincu-
bated at a concentration of 100 mg/ml in 480 mM LiCl and
trifluoroethanol, was added. Absortion at 390 nm was measured
over 30 min with a Beckman Coulter DU 800 spectrophotometer.
Cytokine mRNA analysis
For the measurement of mRNA steady state levels in immune
cells, 2610
5 to 1610
6 cells were lysed in TRI reagent (Molecular
Research Center, Cincinnati, OH) and processed as already
described [13]. Total RNA was extracted as described by the
manufacturer. The synthesis of first strain cDNA was performed
using the manufacturer’s protocol (Qiagen Inc. Valencia, CA).
Briefly, total RNA was resuspended in a final volume of 20 ml
containing 4 units of Omniscript, 2 mlo f1 0 6RT buffer, 2 mlo f
5 mM dNTP, 20 units of RNase inhibitor and 1 ml of random
hexamer primers (27 OD/ml) (Invitrogen, Carlsbad, CA) and
incubated at 37uC for 60 min. 1/10 to 1/20 of the RT products
were used for the real time PCR (qPCR). The primers were
selected using the Primer Express software and the SYBR green
master mix from Applied Biosystems was used as recommended by
the manufacturer. For each set of primers, the efficiency of the
PCR was determined after serial dilutions of the cDNA. The PCR
efficiencies were . 90% and allowed the DDCT calculations
relative to b-actin (Rat) or 18S (mouse) in order to calculate the
fold change (2
2DDCT) in mRNA steady state levels between
juglone-treated or untreated groups.
ELISPOT and ELISA
IFN-c measurements in the mouse splenocyte cultures were
determined using an EKISA kit (Biosource, Camarillo, CA). IFN-c
secretion by splenocytes from transplanted rats was evaluated by
ELISPOT (R&D Systems, Minneapolis, MN) as described by the
manufacturer. Triplicates of serial dilutions of cells were cultured
with PMA (10 ng/ml) plus iononycin (1 mM) for 48 hours. The
concentration of IFN-c and IL-2 in the BAL fluid was determined
using an ELISA kit (R&D Systems, Minneapolis, MN). Lavage
fluid was concentrated 10 fold prior to analysis. Lavage recovery
was similar in all animals and the data shown are those from the
concentrated samples.
IFN-c and CXCL-10 expression vectors
pcDNA1 (InVitrogen) was opened at Xba 1 and Xho 1 sites and
PCR products coding for the coding regions of IFN-c and CXCL-
10 inserted via sticky end ligation using standard methods.
Putative clones were sequenced to ensure full length insert was
present in the appropriate orientation. After amplification,
plasmids were precipitated, washed and resuspended in sterile
TE at 1 mg/ml and 100 ml used for insufflation.
Splenocyte survival
The survival of resting, ionomycin plus PMA (I/P) without or with
juglone at 1 (I/P/J1) or 0.1 mM (I/P/J0.1)-treated splenocytes
were determined by propidium iodide staining and flow cytometry
at 24 hours after the beginning of the culture.
Statistics
1-sample t-tests were used for statistical analysis of the data.
ACKNOWLEDGMENTS
The authors wishto thankmembers of the UW-SCOR-asthma group for their
helpfulcomments.WethankCaraWestmarkforproviding mousespleens and
thymus. We also thank Emily Whitesel for her technical assistance.
Author Contributions
Conceived and designed the experiments: JM SE RB ZS. Performed the
experiments: SE RB ZS ZX EH. Analyzed the data: JM SE RB ZS EH RL
MS. Wrote the paper: JM SE RB MS.
REFERENCES
1. Haring JS, Corbin GA, Harty JT (2005) Dynamic regulation of IFN-gamma
signaling in antigen-specific CD8+ T cells responding to infection. J. Immunol.
174: 6791–6802.
2. Yi T, Cuchara L, Wang Y, Koh KP, Ranjbaran H, et al. (2006) Human allograft
arterial injury is ameliorated by sirolimus and cyclosporine and correlates with
suppression of interferon-gamma. Transplantation 81: 559–566.
Pin1 Modulates Immune Response
PLoS ONE | www.plosone.org 8 February 2007 | Issue 2 | e2263. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an
overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163–189.
4. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB (1989) Regulation
of lymphokine messenger RNA stability by a surface-mediated T cellactivation
pathway. Science 244: 339–343.
5. Mavropoulos A, Sully G, Cope AP, Clark AR (2005) Stabilization of IFN-
gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells.
Blood 105: 282–288.
6. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is
a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.
Cell 66: 807–8015.
7. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP (2002) Role of Pin1 in the
regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in
response to DNA damage. J. Biol. Chem. 277: 47976–47979.
8. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, et al. (2000) Pin1-dependent
prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins.
Mol. Cell 6: 873–883.
9. Lu KP, Hanes SD, Hunter T (1996) A human peptidyl-prolyl isomerase essential
for regulation of mitosis. Nature 380: 544–547.
10. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, et al. (2001) Pin1 is overexpressed
in breast cancer and cooperates with Ras signaling in increasing the
transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20: 3459–3472.
11. Ayala G, Wang D, Wulf G, Frolov A, Li R, et al. (2003) The prolyl isomerase
Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 63:
6244–6251.
12. Shen ZJ, Esnault S, Malter JS (2005) The peptidyl-prolyl isomerase Pin1
regulates the stability of granulocyte-macrophage colony-stimulating factor
mRNA in activated eosinophils. Nat. Immunol. 6: 1280–1287.
13. Esnault S, Shen ZJ, Whitesel E, Malter JS (2006) The peptidyl-prolyl isomerase
Pin1 regulates granulocyte-macrophage colony-stimulating factor mRNA
stability in T lymphocytes. J. Immunol. 177: 6999–7006.
14. Shaw G, Kamen R (1986) A conserved AU sequence from the 39 untranslated
region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:
659–667.
15. Bakheet T, Frevel M, Williams BR, Greer W, Khabar KS (2001) ARED: human
AU-rich element-containing mRNA database reveals an unexpectedly diverse
functional repertoire of encoded proteins. Nucleic Acids Res. 29: 246–254.
16. Lu KP (2004) Pinning down cell signaling, cancer and Alzheimer’s disease.
Trends Biochem. Sci. 29: 200–209.
17. Hennig L, Christner C, Kipping M, Schelbert B, Rucknagel KP, et al. (1998)
Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by
juglone. Biochemistry 37: 5953–5960.
18. Haque MA, Mizobuchi T, Yasufuku K, Fujisawa T, Brutkiewicz RR, et al.
(2002) Evidence for immune responses to a self-antigen in lung transplantation:
role of type V collagen-specific T cells in the pathogenesis of lung allograft
rejection. J. Immunol. 169: 1542–1549.
19. Sekine Y, Bowen LK, Heidler KM, Van Rooijen N, Brown JW, et al. (1997)
Role of passenger leukocytes in allograft rejection: effect of depletion of donor
alveolar macrophages on the local production of TNF-alpha, T helper 1/T
helper 2 cytokines, IgG subclasses, and pathology in a rat model of lung
transplantation. J. Immunol. 159: 4084–4093.
20. Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, et al. (2002) Differential
expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-
inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha
chemoattractant in human cardiac allografts: association with cardiac allograft
vasculopathy and acute rejection. J. Immunol. 169: 1556–1560.
21. Hauser IA, Spiegle S, Kiss E, Gauer S, Sichler O, et al. (2005) Prediction of
acute renal allograft rejection by urinary monokine induced by IFN-gamma
(MIG). J. Am. Soc. Nephrol. 16: 1849–1858.
22. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N (2001) Donor-
derived IP-10 initiates development of acute allograft rejection. J. Exp. Med.
193: 975–980.
23. Nickel P, Presber F, Bold G, Biti D, Schonemann C, et al. (2004) Enzyme-linked
immunosorbent spot assay for donor-reactive interferon-gamma-producing cells
identifies T-cell presensitization and correlates with graft function at 6 and 12
months in renal-transplant recipients. Transplantation 78: 1640–1646.
24. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, et al. (2003)
Proinflammatory functions of vascular endothelial growth factor in alloimmu-
nity. J. Clin. Invest. 112: 1655–1665.
25. Mizobuchi T, Yasufuku K, Zheng Y, Haque MA, Heidler KM, et al. (2003)
Differential expression of Smad7 transcripts identifies the CD4+CD45RChigh
regulatory T cells that mediate type V collagen-induced tolerance to lung
allografts. J. Immunol. 171: 1140–1147.
26. Duncan MD, Wilkes DS (2005) Transplant-related immunosuppression: a review
of immunosuppression and pulmonary infections. Proc. Am. Thorac. Soc. 2:
449–455.
27. Pierog J, Gazdhar A, Stammberger U, Gugger M, Hyde S, et al. (2005)
Synergistic effect of low dose cyclosporine A and human interleukin 10
overexpression on acute rejection in rat lung allotransplantation. Eur. J.
Cardiothorac. Surg. 27: 1030–1035.
28. Gothel SF, Marahiel MA (1999) Peptidyl-prolyl cis-trans isomerases, a super-
family of ubiquitous folding catalysts. Cell Mol. Life Sci. 55: 423–436.
29. Chao SH, Greenleaf AL, Price DH (2001) Juglone, an inhibitor of the peptidyl-
prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res. 29:
767–773.
30. Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, et al. (2001) CXCR3 and
its ligand CXCL10 are expressed by inflammatory cells infiltrating lung
allografts and mediate chemotaxis of T cells at sites of rejection. Am. J. Pathol.
158: 1703–1711.
31. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, et al. (2000) Requirement of
the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192:
1515–1520.
32. van Besouw NM, Zuijderwijk JM, Vaessen LM, Balk AH, Maat AP, et al. (2005)
The direct and indirect allogeneic presentation pathway during acute rejection
after human cardiac transplantation. Clin. Exp. Immunol. 141: 534–540.
33. Kitade H, Kawai M, Koshiba T, Giulietti A, Overbergh L, et al. (2004) Early
accumulation of interferon-gamma in grafts tolerized by donor-specific blood
transfusion: friend or enemy? Transplantation 78: 1747–1755.
34. Hodge G, Hodge S, Reynolds P, Holmes M (2005) Intracellular cytokines in
blood T cells in lung transplant patients–a more relevant indicator of
immunosuppression than drug levels. Clin. Exp. Immunol. 139: 159–164.
35. Nickel P, Presber F, Bold G, Biti D, Schonemann C, et al. (2004) Enzyme-linked
immunosorbent spot assay for donor-reactive interferon-gamma-producing cells
identifies T-cell presensitization and correlates with graft function at 6 and 12
months in renal-transplant recipients. Transplantation 78: 1640–1646.
Pin1 Modulates Immune Response
PLoS ONE | www.plosone.org 9 February 2007 | Issue 2 | e226